Design, optimization, characterization of dapagliflozin loaded nlc using box-behnken design

Ritesh; Himanshu Chaurasia; Ranjit Singh

doi:10.53730/ijhs.v6nS3.7932

Authors

Ritesh AdarshVijendra Institute of Pharmaceutical Sciences, Saharanpur, Uttar Pradesh
Himanshu Chaurasia AdarshVijendra Institute of Pharmaceutical Sciences, Saharanpur, Uttar Pradesh
Ranjit Singh AdarshVijendra Institute of Pharmaceutical Sciences, Saharanpur, Uttar Pradesh

Keywords:

dapagliflozin, NLC, Box-Behnken design, emulsion–evaporation method, hot homogenizaion method, particle sizes, entrapment efficiency, DSC, TEM

Abstract

Dapagliflozin used to improve glycemic control, along with diet and exercise, in adults with type 2 diabetes is the model drug selected in the present research titled Design, Optimization, and Characterization of Dapagliflozin Loaded NLC Using Box-Behnken Design. Nano formulations are capable of providing site-specific delivery of anti-diabetic molecules to their specific site of action; this enhances the loco-regional concentration of the drug and reduces the systemic side-effects. Dapagliflozin loaded NLCs were prepared by emulsion–evaporation technique using Stearic acid as lipid and tweens & spans as surfactant. NLCs were characterized for particle size, zeta potential, entrapment efficiency and % drug release. The effects of composition of lipid materials and surfactant mixture and homogenization speed on the particle size, zeta potential, drug entrapment efficiency and in vitro drug release behavior were optimized. The optimized formulation OPT-DP-NLC has shown a particle size, entrapment efficiency and Zeta potential within projected limits, at 69.99 nm, 81.94% and -28.99 respectively.

Downloads

Download data is not yet available.

References

Gadadare, R., Mandpe, L., Pokharka, V., 2015. Ultra rapidly dissolving repaglinide nanosized crystals prepared via bottom-up and top-down approach: influence of food on pharmacokinetics behavior. AAPS PharmSciTech.16(4), 787-799.

Veiseh, O., Tang, B.C., Whitehead, K.A., Anderson, D.G., Langer, R., 2015. Managing diabetes with nanomedicine: Challenges and opportunities. Nat Rev Drug Discov. 14, 45-57.

Matthaei, S., Stumvol,l M., Kellere,r M., Haring, H.U., 2000. Pathophysiology and pharmacological treatment of insulin resistance. Endocr Rev. 21, 585–618.

Nimase, P.K., Vidyasaga,r G., Suryawanshi, D.M., Bathe, R.S.,2013. Nanotechnology and diabetes. Int J Adv Pharmaceutics. 2, 145-148.

Zanchetta, B., Chaud, M., Santana, M., 2015. Self-emulsifying drug delivery systems (SEDDS) in pharmaceutical development. J. Adv. Chem. Eng. 5, 1–7, 2015.

Aslam, M., Aqi,l M., Ahad, A., Najmi, A.K., Sultana, Y., Ali, A.,2016. Application of Box–Behnken design for preparation of glibenclamide loaded lipid based nanoparticles: Optimization, in vitro skin permeation, drug release and in vivo pharmacokinetic study. Journal of Molecular Liquids. 219, 897-908.

Alam, S., Aslam, M., Khan, A., 2016. Nanostructured lipid carriers of pioglitazone for transdermal application: from experimental design to bioactivity detail. Drug Deliv. 23(2), 601-609.

Chen, H., Zhong, Q., 2014. Processes improving the dispersibility of spray-dried zein nanoparticles using sodium caseinate. Food Hydrocolloids. 35, 358–366.

Teixeira, J., 1998. Small-angle scattering by fractal systems. J. Appl. Crystallogr. 21 (6), 781–785.

Maringanti, P.S., Nalagonda, C., 2013. Formulation and evaluation of sitagliptin phosphate and metformin hydrochloride trilayered tablets. Int J Drug Deliv. 5, 15.

Kasim, N.A., Whitehouse, M., Ramachandran, C., Bermejo, M., Lennernäs, H., Hussain, A.S, Junginger, E., Stavchansky, S.A., Midha, K.K., Shah, V.P., Amidon, G.L.,2004. Molecular properties of WHO essential drugs and provisional biopharmaceutical classiﬁcation. Mol. Pharm. 1 (1), 85–96.

Ahmadi, A., Khalili, M., Farsadrooh, M., Ghiasi, M., Nahri-Niknafs, B.,2013. Antihyperglycemic and antihyperlipidemic effects of newly synthesized glibenclamide analogues on streptozotocin-diabetic rats. Drug Res. 63 (12).

Arya, A.K., Kumar, L., Pokharia, D., Tripathi, K., 2008. Applications of nanotechnology in diabetes. Dig J NanomaterBiostruct. 3, 221-225.

Sharma, G., Sharma, A.R., Nam, J.S., Doss, G.P.C., Lee, S.S., 2015. Nanoparticle based insulin delivery system: The next generation efficient therapy for Type 1 diabetes. Nanobiotechnol.13, 74.

Mudshinge, S.R., Deore, A.B., Patil, S., Bhalgat, C.M., 2011. Nanoparticles: Emerging carriers for drug delivery. Saudi Pharm J.19(3), 129-141.

Hasan, A.A., Madkor, H., Wageh, S., 2013. Formulation and evaluation of metformin hydrochloride-loaded niosomes as controlled release drug delivery system. Drug Deliv. 20(3-4), 120-126.

Elbahwy, I.A., Ibrahim, H.M, Ismael, H.R., Kasem, A.A., 2017. Enhancing bioavailability and controlling the release of glibenclamide from optimized solid lipid nanoparticles. J. Drug Delivery Sci. Technol. 38, 78–89.

Herman, G.A., Bergman, A., Liu, F., 2006. Pharmacokinetics and pharmacodynamic effects of the oral DPP-4 inhibitor sitagliptin in middle-aged obese subjects. J Clin Pharmacol. 46, 876–886.

Tamjidi, F., Shahedi, M., Varshosaz, J., Nasirpour, A., 2013. Nanostructured lipid carriers (NLC): A potential delivery system for bioactive food molecules. Innov. Food Sci. Emerg. Technol.2013:19, 29–43.